WO2020116640A1 - Conjugué de médicament, conjugué de polymère et composition d'administration de médicament - Google Patents

Conjugué de médicament, conjugué de polymère et composition d'administration de médicament Download PDF

Info

Publication number
WO2020116640A1
WO2020116640A1 PCT/JP2019/047917 JP2019047917W WO2020116640A1 WO 2020116640 A1 WO2020116640 A1 WO 2020116640A1 JP 2019047917 W JP2019047917 W JP 2019047917W WO 2020116640 A1 WO2020116640 A1 WO 2020116640A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
drug
group
conjugate
targeting
Prior art date
Application number
PCT/JP2019/047917
Other languages
English (en)
Japanese (ja)
Inventor
オラシオ カブラル
拓也 宮崎
Original Assignee
国立大学法人 東京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 東京大学 filed Critical 国立大学法人 東京大学
Priority to JP2020560070A priority Critical patent/JPWO2020116640A1/ja
Publication of WO2020116640A1 publication Critical patent/WO2020116640A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Definitions

  • the present invention relates to a drug conjugate and a polymer conjugate containing a phosphocholine group, and a drug delivery composition containing the polymer conjugate.
  • DDS drug delivery system
  • Non-Patent Documents 1 to 3 are examples of techniques utilizing triphenylphosphonium as a ligand molecule.
  • the present invention has been made to solve the above problems, and its main purpose is to provide a technique for efficiently delivering a drug into cells or mitochondria.
  • the inventors of the present invention have conducted extensive studies to solve the above problems, and by introducing a targeting site containing a phosphocholine group into a drug to be delivered or a carrier carrying the drug or a component thereof, cancer cells and mitochondria The inventors have found that the directivity to can be imparted, and have completed the present invention.
  • a drug complex comprising a drug and a targeting site bound to the drug, wherein the targeting site is represented by the following formula (I):
  • Drug conjugates are provided that include a phosphocholine group.
  • a polymer conjugate comprising a drug delivery polymer and a targeting moiety bound to the drug delivery polymer, wherein the targeting moiety is represented by the above formula (I).
  • the polymer conjugate containing the phosphocholine group represented by these is provided.
  • the drug delivery polymer comprises a hydrophilic polymer segment and a hydrophobic polymer segment.
  • the polymer conjugate further has a drug bound thereto.
  • a composition for drug delivery which comprises the polymer conjugate.
  • the drug delivery composition further comprises a drug.
  • a method for producing a compound having targeting property which comprises a step of binding a compound to be delivered and a compound having a phosphocholine group represented by the above formula (I).
  • the target of delivery is directed to cells or mitochondria, which comprises modifying the target of delivery with a targeting site containing a phosphocholine group represented by the above formula (I).
  • a method of granting is provided.
  • the delivery target is selected from liposomes, polymeric micelles, polyion complexes, polyplexes, lipoplexes, lipopolyplexes, inorganic metal particles, lipid nanoparticles and gels.
  • the present invention also relates to the use of a compound having a phosphocholine group represented by the above formula (I) or a compound having a phosphocholine group represented by the above formula (I) for the production of a compound having a directivity to cells or mitochondria. ..
  • a detection reagent comprising a targeting site and labeled with a labeling substance, wherein the targeting site has a phosphocholine group represented by the above formula (I). Detection reagents are provided that include.
  • a positive charge is favorable for electrostatic interaction with a negatively charged cell membrane, and a hydrophobic property is preferable because it has high affinity with a hydrophobic cell membrane surface.
  • Triphenylphosphonium which has been used as the conventional targeting site, is in line with the design policy, is hydrophobic, and has a positive charge.
  • the charge is neutralized as a whole, and by utilizing a hydrophilic phosphocholine group as the targeting site, the targeting site is controlled while controlling the biodistribution. Good cell uptake and directivity to mitochondria can be imparted to the bound drug or carrier. This is because the phosphocholine group whose charge is neutralized can reduce non-specific interactions with normal tissues and proteins and can utilize the phospholipid and phospholipid derivative uptake functions of cells and mitochondria. Conceivable.
  • Fig. 6 is a graph showing the cellular uptake level of albumin PC conjugate.
  • 3 is a graph showing the localization level of albumin PC conjugate in mitochondria. It is a TEM observation image which shows transfer of gold nanoparticles loaded with PC to mitochondria.
  • a drug conjugate (conjugate) in one embodiment of the present invention comprises a drug and a targeting site bound to the drug, and the targeting site is represented by the following formula (I). Containing a phosphocholine group.
  • the drug is not particularly limited, and a drug having a desired activity can be used.
  • a drug that is desired to be delivered intracellularly for example to mitochondria, is used.
  • a drug refers to a substance having some physiological activity.
  • the physiological activity possessed by the drug may be any physiological activity that can function as an active ingredient of a drug, and examples thereof include antitumor activity, immunostimulatory activity, antiviral activity, antibacterial activity, and anti-inflammatory activity.
  • the drug may be a protein such as an enzyme, hormone, vaccine, antibody, mRNA, pDNA, antisense, ribozyme, siRNA, decoy nucleic acid, nucleic acid such as aptamer, and high molecular drug such as polysaccharide.
  • the drug and the targeting moiety may be directly bonded or indirectly bonded via a linker moiety.
  • the drug conjugate of the present invention can be represented by the following formula (II).
  • L 0 represents a single bond or a divalent atomic group
  • D represents a drug residue
  • s represents an integer of 1 to 2000.
  • the divalent atomic group that can be represented by L 0 is not particularly limited as long as the effects of the present invention can be obtained.
  • the divalent atomic group is, for example, an atomic group formed by a reaction of a compound having a functional group capable of binding with a functional group of a drug, which will be described later, and a targeting site, and the drug. And the residue of the compound of interest.
  • the divalent atomic group includes, for example, a linear or branched alkylene group having 1 to 6 carbon atoms, —COO—, —CONH—, —NH—, —CO—, —O—, —S—, and these It can be any combination.
  • the number of atoms in the main chain of the divalent atomic group can be, for example, 1 to 20, preferably 1 to 15, and more preferably 1 to 10.
  • S represents the number of targeting sites bound to the drug (the number of bonds per molecule).
  • s can be appropriately selected depending on the chemical structure, three-dimensional structure, molecular weight, etc. of the drug. For example, when the drug has a large molecular weight (such as when the drug is a macromolecular drug), s may be 2 or more, for example, 2 to 200, or 2 to 100 or 2 to 50.
  • the above drug conjugate may be prepared by any suitable method. For example, by using a compound having a functional group capable of binding to a functional group of a drug and a targeting site, by reacting the functional group of the compound with the functional group of the drug, a targeting site can be obtained. A drug complex bound with a drug can be obtained.
  • the functional group possessed by the drug may be intrinsic in the drug or may be additionally introduced.
  • the combination of the functional groups include, for example, thiol group and (meth)acryloyl group, thiol group and maleimide group, thiol group and thiol group, thiol group and carboxyl group, (meth)acryloyl group and hydroxyl group, ( Examples thereof include a (meth)acryloyl group and an amino group, a carboxyl group and an amino group, a carboxyl group and a hydroxyl group, and an amino group and a hydroxyl group.
  • any appropriate compound having the functional group capable of binding to the functional group of the drug and the targeting site any appropriate compound having the functional group and the phosphocholine group can be used.
  • Specific examples include 2-(meth)acryloyloxyethylphosphorylcholine, 3-(meth)acryloyloxypropylphosphorylcholine, 4-(meth)acryloyloxybutylphosphorylcholine, 6-(meth)acryloyloxyhexylphosphorylcholine, 10-(meth) Acryloyloxydecylphosphorylcholine, ⁇ -(meth)acryloyl(poly)oxyethylenephosphorylcholine, 2-(meth)acrylamidoethylphosphorylcholine, 3-(meth)acrylamidopropylphosphorylcholine, 4-(meth)acrylamidobutylphosphorylcholine, 6-(meth) Examples thereof include acrylamidohexylphosphorylcholine, 10-(meth)acrylamidedecylphosphorylcholine, and ⁇ -
  • any suitable polymer applicable in the field of DDS can be used, and for example, a conventionally known known polymer for drug delivery can be preferably used.
  • Examples of the known drug delivery polymer include a chargeable polymer capable of forming a polyion complex (PIC) by associating with a charged drug by electrostatic interaction, and a block copolymer capable of forming a drug-encapsulating polymer micelle.
  • PIC polyion complex
  • Preferable examples include, biocompatible polymers capable of forming microparticles capable of supporting a drug, and water-soluble polymers used for modifying a delivery target.
  • a cationic polymer and an anionic polymer may be used depending on the kind of charge as the polymer. It is divided into
  • the above cationic polymer is a polymer having a cationic group and having a positive charge at physiological pH.
  • the cationic polymer may have some anionic groups as long as the cationic properties of the polymer as a whole are not hindered.
  • the cationic polymer may be composed of a single repeating unit, and may contain two or more kinds of repeating units in any combination and ratio.
  • the cationic polymer may be a polymer containing an amino group in the main chain or a polymer containing an amino group in the side chain.
  • polymers containing an amino group in the main chain include polyethyleneimine.
  • polymer having an amino group in the side chain examples include a polyamino acid containing an amino acid having an amino group in the side chain as a monomer unit or a derivative thereof.
  • polyamino acid containing an amino acid having an amino group in the side chain as a monomer unit or a derivative thereof examples include polyaspartamide, polyglutamide, polylysine, polyarginine, polyhistidine, and derivatives thereof.
  • poly(Asp-AP) or poly(Asp-AP) in which aminopentane (AP) is introduced into the side chain carboxylic acid of aspartic acid (glutamic acid) (Glu-AP)
  • polyaspartic acid or polyglutamic acid
  • DET H 2 NCH 2 CH 2 NH-CH 2 CH 2 NH 2
  • Poly(Asp-DET) or poly(Glu-DET) in which DET is introduced is preferably used.
  • the polyamino acid or its derivative containing an amino acid having an amino group in its side chain as a monomer unit may further contain an uncharged amino acid having a hydrophobic group in its side chain as a monomer unit, if necessary.
  • the uncharged amino acid having a hydrophobic group in its side chain include amino acids having a solubility of 5 g or less in 100 g of water at 25° C., and more preferably 4 g or less.
  • Examples of such amino acids include non-polar natural amino acids such as leucine, isoleucine, phenylalanine, methionine, and tryptophan, and hydrophobic derivatives of amino acids having a hydrophobic group introduced into their side chains.
  • the hydrophobic derivative of an amino acid is preferably a hydrophobic derivative of an acidic amino acid such as aspartic acid or glutamic acid.
  • the introduced hydrophobic group include a saturated or unsaturated linear or branched aliphatic hydrocarbon group having 6 to 27 carbon atoms, an aromatic hydrocarbon group having 6 to 27 carbon atoms, or a cholesterol residue. It can be preferably exemplified.
  • the above anionic polymer is a polymer having an anionic group and having a negative charge at physiological pH.
  • the anionic polymer may have some cationic groups as long as the anionicity of the polymer as a whole is not impaired.
  • the anionic polymer may be composed of a single repeating unit, and may contain two or more kinds of repeating units in any combination and ratio.
  • examples of the anionic polymer include a polymer containing a monomer unit containing a carboxyl group, a polymer containing a monomer unit containing a sulfate group, a polymer containing a monomer unit containing a phosphoric acid group, and the like.
  • the monomer unit containing a carboxyl group is preferably an amino acid containing a carboxyl group in its side chain, and examples thereof include aspartic acid and glutamic acid.
  • the targeting site is bound to any appropriate site.
  • it may be attached to one or both ends of the polymer, or it may be introduced into a side chain.
  • the number of targeting moieties bound to the polymer (the number of bonds per molecule of the polymer) is not limited as long as the effect of the present invention can be obtained, and may be 1 or 2 or more.
  • the binding between the polymer and the targeting moiety is performed by using a compound having a functional group capable of binding to a functional group of the polymer and the targeting moiety, and linking the drug according to the item A with the targeting moiety. It can be performed in the same manner as the coupling.
  • the block copolymer capable of forming the polymer micelle capable of encapsulating the drug is typically a block copolymer containing a hydrophilic polymer segment and a hydrophobic polymer segment, and preferably these It is a block copolymer in which segments are connected in series.
  • polyethylene glycol polypropylene glycol, poly(2-oxazoline), polysaccharide, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylamide, polymethacrylamide, polyacrylic acid ester, polymethacrylic acid ester, etc.
  • polyethylene glycol can be preferably used.
  • the hydrophilic polymer segment may be linear or branched.
  • the block copolymer is more hydrophilic than the hydrophilic polymer segment to the extent that it can form micelles with the hydrophilic polymer segment facing outward and the hydrophobic polymer segment facing inward in an aqueous solvent.
  • a polymer having a low hydrophilicity is also selected. Examples of such polymers include polyglycolic acid (PGA), polylactic acid (PLA) and its copolymers (PLGA), polyamino acids and their derivatives, polyethers and their derivatives, and polyamino acids and their derivatives. , Polyethers and their derivatives can be preferably used.
  • polyamino acid one or more amino acids selected from amino acids containing an amino group in the side chain, uncharged amino acids containing a hydrophobic group in the side chain, amino acids containing a carboxyl group in the side chain, or A polyamino acid containing a derivative as a monomer unit or a derivative thereof can be preferably used.
  • the amino acid having an amino group in its side chain include basic amino acids such as lysine, arginine, histidine, ornithine, and amino acid derivatives having an amino group introduced into the side chain of acidic amino acids such as aspartic acid and glutamic acid.
  • the uncharged amino acid containing a hydrophobic group in the side chain and the amino acid containing a carboxyl group in the side chain are as described above.
  • the polyamino acid the chargeable polymer described in the section B-1 can also be used.
  • the above-mentioned polyether includes polyglycidyl ether having a side chain structure.
  • block copolymers are described in WO2007/099660, WO2007/099661, WO2010/093036, WO2012/096399, WO2014/133172, WO2015/170757, etc. Incorporated by reference).
  • the targeting site can be bound to any appropriate site, and is preferably bound to the end on the hydrophilic polymer segment side.
  • the number of targeting moieties attached to the polymer is not limited as long as the effects of the present invention can be obtained, and may be 1 or 2 or more.
  • the polymer and the targeting moiety can be bound by the same method as the method described in Section A for binding the drug and the targeting moiety.
  • a polymer conjugate having a structure in which a targeting site is bound to a block copolymer can be represented by, for example, the formula: ZA 1 -B 1 (wherein Z is a phosphocholine represented by the formula (I)). Represents a group, A 1 represents a hydrophilic polymer segment, and B 1 represents a hydrophobic polymer segment).
  • Z represents a phosphocholine group represented by the formula (I);
  • L 1 , L 2 , L 3 , and L 4 each independently represent a divalent linking group;
  • R 1 is a hydrogen atom, an unsubstituted or substituted straight-chain or branched alkyl group having 1 to 12 carbon atoms, or an unsubstituted or substituted straight-chain or branched alkylcarbonyl group having 1 to 24 carbon atoms.
  • R 2 represents a hydroxyl group, an oxybenzyl group, —O—R 2a or NH—R 2b group, wherein each of R 2a and R 2b independently represents an unsubstituted or substituted straight or branched carbon atom.
  • R 3a , R 3b , R 4a and R 4b each independently represent a methylene group or an ethylene group
  • R 5a and R 5b each independently represent -O- or NH-
  • R 6a and R 6b independently of each other represent a hydrogen atom or a hydrophobic organic group
  • R 7a and R 7b independently of each other, are the following groups: -NH-(CH 2 ) p1 -[NH-(CH 2 ) q1 -] r1 NH 2 (i); -NH- (CH 2) p2 -N [- (CH 2) q2 -NH 2] 2 (ii); -NH-(CH 2 ) p3 -N ⁇ [-(CH 2 ) q3 -NH 2 ][-(CH 2 ) q4 -NH-] r2 H ⁇ (iii); -NH-(CH 2 ) p4 -N ⁇ -(CH 2 )
  • L 1 and L 3 are each independently, for example, a linear or branched alkylene group having 1 to 6 carbon atoms, —COO—, —CONH—, —NH—, —CO—, —O—, —S. -, and any combination thereof.
  • the number of main chain atoms of the divalent linking group can be, for example, 1 to 20, preferably 1 to 15, and more preferably 1 to 10.
  • Specific examples include -SCH 2 CHCOH-, -SS-, -SCO-, -OCH 2 CHCOH-, -NHCH 2 CHCOH-, -NHCOO-, -CH 2 CH 2 SCH 2 CH(CH 3 )COOCH 2 CH. 2- and the like.
  • the L 2 is, for example, -NH -, - O -, - O-L 2a -NH -, - CO -, - CH 2 -, and -NH- O-L 2a -S-L 2a ( here, L 2a is independently an alkylene group having 1 to 6 carbon atoms).
  • L 4 may be, for example, a linking group selected from —OCO—L 4a —CO—, and NHCO—L 4a —CO— (wherein L 4a is an alkylene group having 1 to 6 carbon atoms).
  • Examples of the linear or branched alkyl group having 1 to 12 carbon atoms which is defined by the groups of R 1 , R 2a and R 2b , include, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n -Butyl group, sec-butyl group, tert-butyl group, n-hexyl group, decyl group, undecyl group and the like can be mentioned.
  • the straight-chain or branched alkyl moiety having 1 to 12 carbon atoms in the straight-chain or branched alkylcarbonyl group having 1 to 24 carbon atoms defined by the group of R 1 can be referred to the above-mentioned examples.
  • Examples of the alkyl moiety having 13 or more carbon atoms include a tridecyl group, a tetradecyl group, a pentadecyl group, a nonadecyl group, a docosanyl group, and a tetracosyl group.
  • the substituent in the case of “substituted” is not limited, but is a C 1-6 alkoxy group, an aryloxy group, an aryl C 1-3 oxy group, a cyano group, a carboxyl group.
  • Group, amino group, C 1-6 alkoxycarbonyl group, C 2-7 acylamido group, tri-C 1-6 alkylsiloxy group, siloxy group, silylamino group, or an acetalized formyl group, formyl group, chlorine or Halogen atoms such as fluorine can be mentioned.
  • a display such as C 1-6 means that the carbon number is 1 to 6.
  • the hydrophobic organic group defined by the groups of R 6a and R 6b is, for example, a saturated or unsaturated linear or branched aliphatic hydrocarbon group having 6 to 27 carbon atoms, or an aryl group having 6 to 27 carbon atoms.
  • R 7a and R 7b groups are preferably, independently of one another, a group of formula (i) or (v).
  • formula (i) it is preferable that p1 and q1 are each independently 2 or 3, and more preferably 2.
  • r1 is preferably an integer of 1 to 3.
  • the above R 8 group is preferably a side chain of lysine or ornithine.
  • A”, “b”, “c”, “d”, and “e” representing the number of repetitions of each amino acid residue are each independently an integer of preferably 0 to 300, more preferably an integer of 0 to 250.
  • the polymerization degree (a+b+c+d+e) of the polyamino acid is preferably an integer of 10 to 300, more preferably an integer of 20 to 250.
  • K which represents the repeating number of ethylene glycol, preferably represents an integer of 40 to 2,000, more preferably 45 to 1,000.
  • the polymer complex represented by the above formula (III) or (IV) can be obtained by, for example, purifying polyethylene glycol having a functional group at the ⁇ -terminal and a desired polyamino acid as they are, or if necessary, after purifying so as to narrow the molecular weight distribution. It can be formed by preparing a block copolymer by coupling by a known method, and utilizing a functional group at the ⁇ -terminal of the block copolymer to cause condensation or addition reaction of a compound having a targeting site. The binding of the targeting site may be performed after the micelle formation described below.
  • polyethylene glycol having a functional group at the ⁇ -terminal and an amino group at the ⁇ -terminal is prepared, and ⁇ -benzyl-L-aspartate is introduced from the amino terminal.
  • ⁇ -benzyl-L-glutamate, N ⁇ -ZL-lysine, N-carboxylic acid anhydride (NCA) of a protected amino acid is polymerized, and if necessary, the side chain of the obtained polyamino acid is depolymerized.
  • a block copolymer is prepared by protecting and/or introducing groups (i) to (v), and the functional group at the ⁇ -terminal of the block copolymer is used to condense or add a compound having a targeting moiety. It can be formed by reacting. The binding of the targeting site may be performed after the micelle formation described below.
  • a structural change for example, formation of an imide ring by dealcoholization of an amino acid ester residue
  • the block copolymer contains a residue that undergoes such a structural change is also included in the above formulas (III) and (IV).
  • some NH groups and NH 2 groups in the cationic amino acid residue may be converted to salts (mainly hydrochloride) due to the use of acid (mainly hydrochloric acid) in the synthetic process.
  • acid mainly hydrochloric acid
  • Z represents a phosphocholine group represented by the formula (I);
  • L 5 and L 6 each independently represent a single bond or a divalent linking group;
  • R 9 represents a hydrogen atom, an unsubstituted or substituted straight-chain or branched alkyl group having 1 to 12 carbon atoms, or an unsubstituted or substituted straight-chain or branched alkylcarbonyl group having 1 to 24 carbon atoms.
  • R 10 represents a primary amine through an alkylene group or an ester bond;
  • m represents an integer of 5 to 20,000;
  • n represents an integer of 2 to 5,000.
  • Examples of the primary amine having an alkylene group or an ester bond defined for R 10 include those represented by the following formula (VI) or (VII).
  • R 11 is a hydrogen atom or the following formula (VIII)
  • R 12 is a linear or branched hydrocarbon group having 1 to 20 carbon atoms, a phenyl group which may have a substituent, or a heterocyclic functional group which may have a substituent.
  • heterocyclic functional group which may have a substituent defined for R 12 above include an indolyl ring, a pyrrolidone group, a furan ring, a pyridine ring, a morpholine ring, an epoxy ring, a purine ring and a pyrimidine ring. Can be mentioned.
  • x is, for example, 1, 2 or 3, and can be, for example, 1 or 2, and also 1, for example.
  • y and w are each independently, for example, 1, 2 or 3, and can be, for example, 1 or 2, and also 1, for example.
  • R 12 can also be, for example, an indolyl ring.
  • L 5 is, for example, a linear or branched alkylene group having 1 to 6 carbon atoms, —COO—, —CONH—, —NH—, —CO—, —O—, —S—, or any of these. It can be a combination.
  • the number of main chain atoms of the divalent linking group can be, for example, 1 to 20, preferably 1 to 15, and more preferably 1 to 10. Specific examples include —NHCOCH 2 CH 2 —, —CH 2 CH 2 NHCH 2 CH 2 —, —CH 2 CH 2 SCH 2 CH 2 —, and —CH 2 CH 2 OCH 2 CH 2 —.
  • the above L 6 is, for example, a single bond or —CH 2 CH 2 O—.
  • M is preferably an integer of 40 to 2,000, more preferably 45 to 1,000. Further, n represents an integer of preferably 10 to 300, more preferably 20 to 250.
  • the polymer complex represented by the above formula (V) is prepared, for example, by preparing polyethylene glycol having a functional group at the ⁇ -terminal, epichlorohydrin, 1,2-epoxy-5-hexene, 1-allyl-2,3. -Epoxy ring-opening polymerization using epoxy group-containing monomers such as epoxypropane, epibromohydrin, 3,4-epoxy-1-butane, 1,2-epoxy-9-decene, 2,3-epoxypropylpropargyl ether
  • condensation or addition of a compound having a targeting site It can be obtained by a method including reacting and introducing a primary amine into a side chain of a polyglycidyl chain of a block copolymer having a targeting site added thereto.
  • the polymer conjugate may have a drug attached to it.
  • the drug may be introduced at the side chains and/or the ends of the hydrophobic polymer segment of the block copolymer.
  • the number of drugs bound to the polymer is not limited as long as the effects of the present invention can be obtained, and can be, for example, 1 to 200, preferably 2 to 100.
  • the polymer conjugate to which a drug is bound can be represented by, for example, the formula: ZA 2 -B 2 (-D) (wherein Z represents a phosphocholine group represented by the formula (I), A 2 represents the hydrophilic polymer segment, B 2 represents the hydrophobic polymer segment, and D represents the residue of the drug).
  • Z represents a phosphocholine group represented by the formula (I)
  • a 2 represents the hydrophilic polymer segment
  • B 2 represents the hydrophobic polymer segment
  • D represents the residue of the drug.
  • Specific examples include an embodiment in which a drug is bound to the hydrophobic polymer side chain of the polymer complex represented by the above formulas (III) to (V).
  • the block copolymer has a carboxyl group in the side chain of the hydrophobic polymer segment (in formulas (III) and (IV), R 5a ⁇ O, R 6a ⁇ H and/or R 5b ⁇ O, R 6b ⁇ H
  • the drug by reacting the drug having a hydroxyl group with the carboxyl group, the drug can be bound to the side chain of the hydrophobic polymer segment of the block copolymer via an ester bond.
  • the drug can be attached to the hydrophobic polymer segment side chain of the block copolymer by an amide bond formed by the reaction with the drug having a group.
  • biocompatible polymer capable of forming the fine particles capable of supporting the drug examples include polyglycolic acid (PGA), polylactic acid (PLA) and copolymers thereof (PLGA). , Poly ⁇ -caprolactone, chitosan and the like.
  • the targeting site is attached to any suitable site. For example, it may be attached to one or both ends of the polymer, or it may be introduced into a side chain.
  • the number of targeting moieties attached to the polymer is not limited as long as the effects of the present invention can be obtained, and may be 1 or 2 or more.
  • the binding between the polymer and the targeting moiety is performed by using a compound having a functional group capable of binding to a functional group of the polymer and the targeting moiety, and linking the drug according to the item A with the targeting moiety. It can be performed in the same manner as the coupling.
  • water-soluble polymer is used for modification of a delivery target for the purpose of solubilization, sustained release, improvement of blood retention, avoidance of enzymatic degradation, and the like.
  • water-soluble polymers include polyethylene glycol, polypropylene glycol and copolymers thereof, soluble proteins such as albumin, polysaccharides, etc.
  • polyethylene glycol can be preferably used.
  • the target substance to be modified may be a drug or a carrier carrying a drug such as liposome, micelle, gel, gold nanoparticle and the like.
  • a drug such as liposome, micelle, gel, gold nanoparticle and the like.
  • modification with polyethylene glycol PEG modification
  • PEGylated proteins such as PEGylated interferon and PEG-modified liposomes can be obtained.
  • the targeting site is bound to any appropriate site.
  • it may be attached to one or both ends of the polymer, or it may be introduced into a side chain.
  • the number of targeting moieties bound to the polymer (the number of bonds per molecule of the polymer) is not limited as long as the effect of the present invention can be obtained, and may be 1 or 2 or more.
  • the binding between the polymer and the targeting moiety is performed by using a compound having a functional group capable of binding to a functional group of the polymer and the targeting moiety, and linking the drug according to the item A with the targeting moiety. It can be performed in the same manner as the coupling.
  • a polymer complex using a water-soluble polymer that modifies a carrier such as a liposome has a targeting site containing a phosphocholine group represented by the above formula (I) at one end and a carrier surface at the other end. It is preferable to have a group capable of interacting.
  • the polymer conjugate of the formula: may be represented by Z-E-R X (wherein, Z is represents a phosphocholine group represented by the formula (I), E is a water-soluble polymer segment the stands, R X represents a hydrophobic group derived from phospholipids, long chain fatty acids, sterols, etc.).
  • a drug delivery composition comprising the polymer conjugate according to the item B.
  • the drug delivery composition comprises particles formed by the polymer conjugate.
  • the average particle size of the particles may vary depending on the polymer complex used, but is, for example, 1000 nm or less, preferably 400 nm or less, 200 nm or less, 150 nm or less, 100 nm or less, or 80 nm or less, for example, 20 nm or more or 30 nm or more.
  • the average particle diameter of the particles can be measured using a commercially available dynamic light scattering (DLS) measuring device.
  • DLS dynamic light scattering
  • the drug delivery composition may further include a drug in addition to the polymer conjugate.
  • the drug By including the drug, the drug can be carried (eg, encapsulated) in the particles, and the drug can be efficiently delivered into cells and further into mitochondria.
  • This embodiment is particularly useful when the drug is not bound to the polymer conjugate, but it is also possible to use the drug-bound polymer conjugate in combination with the drug.
  • the drug delivery composition may further comprise a drug delivery polymer that does not contain a targeting moiety in addition to the polymer conjugate.
  • a drug delivery polymer containing no targeting moiety the known drug delivery polymers described in the above section B can be used.
  • the combination of polymers can be appropriately selected according to the purpose, and, for example, the block copolymer having the target-directing moiety attached thereto (ie, the polymer complex described in the section B-2) and the target-directing moiety are bound thereto. It can be used in combination with a non-charged polymer.
  • the content ratio (molar ratio) of the polymer complex and the drug delivery polymer containing no targeting site is, for example, 5:95 to 95:5, or 10:90 to 90:. It can be 10.
  • the ratio of the number of moles (N) of the cationic group derived from the cationic polymer to the number of moles (A) of the anionic group derived from the anionic drug in the composition (N) /A ratio) can be, for example, 1 or more, preferably 3 or more, and more preferably 5 to 100.
  • the ratio of the number of moles of the anionic polymer-derived anion group (A) to the number of moles of the cationic group derived from the cationic drug (N) in the composition can be, for example, 1 or more, preferably 3 or more, and more preferably 5 to 100.
  • a polymer micelle can be formed by adding the polymer complex to a buffered aqueous solution as necessary and stirring.
  • the polymer composite is dissolved and mixed in an organic solvent, and the homogenized solution is distilled off under reduced pressure to prepare a polymer film, and water is added to the obtained polymer film and mixed for self-assembly.
  • a polymeric micelle can be formed.
  • the drug is included in the polymer micelle, the micelle may be formed in the presence of the drug.
  • the N/A ratio or A/N ratio in the composition when the block copolymer and the drug having opposite charges are used is as described for the charged polymer.
  • a cross-linking structure may be formed between the hydrophobic polymer segments by using a cross-linking agent or by utilizing a functional group in the side chain.
  • WO2007/099660, WO2007/099661, WO2010/093036, WO2012/096399, WO2014/133172, WO2015/170757 and the like can be referred to.
  • a polymer spherical crystallization method such as emulsion solvent diffusion (ESD) method in water, an emulsion solvent evaporation method, a phase separation method, a phase transition method, etc. Particles carrying the drug can be formed.
  • ESD emulsion solvent diffusion
  • a carrier whose surface is modified with the polymer complex can be obtained by mixing with a carrier in an aqueous solution optionally buffered.
  • a drug can be included in advance in the carrier.
  • a liposome is typically a vesicle formed by a bilayer membrane of phospholipids, can be appropriately prepared by those skilled in the art, and a drug can be included therein.
  • the above drug conjugate or drug delivery composition is administered to an individual in need of administration of a drug.
  • the drug is a drug that is desired to be taken up intracellularly, preferably a drug that is desired to be delivered to the mitochondria.
  • the individual to be administered includes, for example, humans or non-human mammals.
  • the administration method may be oral administration or parenteral administration.
  • Parenteral administration is preferable, and subcutaneous administration, intramuscular administration, intravenous administration, intraperitoneal administration, intrathecal administration and the like can be illustrated.
  • a drug can be efficiently delivered into cells and further localized in mitochondria.
  • a targeting property including a step of binding a compound to be delivered and a compound having a phosphocholine group represented by the formula (I) Methods of making the compounds having are provided.
  • the targeting property imparted to the compound to be delivered is the intracellular targeting, more specifically, the mitochondrial targeting.
  • the compound to be delivered includes a drug or a polymer for drug delivery. Specific examples thereof include the drug described in the section A and the known polymer for drug delivery described in the section B.
  • Any appropriate method can be selected as a method for binding the compound to be delivered and the compound having the phosphocholine group represented by the formula (I).
  • a compound having a functional group capable of reacting with the functional group of the compound to be delivered and a phosphocholine group represented by the formula (I) is selected, and the functional group of the compound and the functional group of the compound to be delivered are selected.
  • Any method of reacting can be used. Specific examples of such a compound include the phosphocholine group-containing compound used in the production of the drug conjugate described in the section A.
  • the delivery target is modified with a targeting site containing a phosphocholine group represented by the above formula (I).
  • a method of imparting a tropism to a cell or mitochondria to a delivery target is provided.
  • the delivery target may be a drug or a carrier carrying the drug.
  • the drug-carrying carrier is not limited as long as it can be applied to DDS, and includes liposomes, polymer micelles, polyion complexes, polyplexes, lipoplexes, lipopolyplexes, inorganic metal particles, lipid nanoparticles, gels and the like. Can be mentioned. These carriers are widely known in the DDS field and can be easily prepared by those skilled in the art.
  • the method for modifying the carrier with the targeting moiety containing the phosphocholine group represented by the formula (I) includes binding the targeting moiety containing the phosphocholine group represented by the formula (I) to the surface of the carrier.
  • the bond is not limited to a covalent bond, and may be a non-covalent bond caused by an intermolecular force such as electrostatic interaction or hydrophobic interaction.
  • the method for modifying the drug is as described in Section A.
  • Modification of the carrier by covalent bonding is, for example, a method of previously binding a target-directing site to a component of the carrier and forming a carrier using the component to which the target-directing site is bound, or a functional group.
  • a carrier so that the functional group is exposed to the surface of the carrier using a component having, and then reacting with a compound having a functional group capable of reacting with the functional group and a targeting site.
  • Specific examples of the former include, for example, a method of forming a carrier by using the polymer composite described in the section B, and more specifically, a polymer micelle formed by using the polymer composite described in the section B-2. There is a method of doing.
  • hydrophilic polymer segment and a hydrophobic polymer segment examples include a hydrophilic polymer segment and a hydrophobic polymer segment, and a functional group (hydroxyl group, carboxyl group, amino group, aldehyde group, thiol group, maleimide group, etc.) at the end of the hydrophilic polymer segment side.
  • Modification of the carrier by non-covalent bonding can be performed, for example, by forming the carrier and then allowing the carrier to interact with a compound having a group capable of interacting with its surface and a targeting site.
  • a compound having a chargeable carrier for example, a chargeable liposome, a polyion complex
  • a charged group having a charge opposite to the carrier and a targeting site for example, at one end
  • a compound having a hydrophobic group and a targeting site eg, PEG having a hydrophobic group at one end and a phosphocholine group at the other end
  • Examples include a method of fixing on the surface.
  • a DDS carrier having a targeting site containing a phosphocholine group on its surface can be obtained.
  • Detection Reagent is a detection reagent containing a targeting site and labeled with a labeling substance, wherein the targeting site is a phosphocholine represented by the above formula (I).
  • a detection reagent is provided that includes a group. Since the phosphocholine group represented by the above formula (I) exhibits directivity to mitochondria, it is possible to suitably observe mitochondria in cells or individuals by using the above detection reagent.
  • any appropriate label may be used as the labeling substance depending on the purpose.
  • fluorescent labels, luminescent substance labels, radiolabels, enzyme labels and the like can be preferably exemplified.
  • the fluorescent label include fluorescent dyes such as Alexa compounds, Cy3, Cy5, phycoetinin, phycocyanin, allophycocyanin, FITC, rhodamine, and lanthanide, or derivatives of these fluorescent dyes, or fluorescent proteins such as green fluorescent protein ( GFP) or the like or a mutant thereof can be used.
  • fluorescent dyes such as Alexa compounds, Cy3, Cy5, phycoetinin, phycocyanin, allophycocyanin, FITC, rhodamine, and lanthanide, or derivatives of these fluorescent dyes, or fluorescent proteins such as green fluorescent protein ( GFP) or the like or a mutant thereof can be used.
  • GFP green fluorescent protein
  • a chemiluminescent substance such as luminol, fluoroscein and rhodamine B, or a bioluminescent substance such as luciferin and iocrine may be used.
  • radioisotopes such as 33 P, 3 H, 14 C, 35 S, 125 I, 32 P, 131 I and the like can be used.
  • an enzyme ⁇ -galactosidase, ⁇ -lactamase, GUS, mustard peroxidase, alkaline phosphatase, luciferase or the like can be used.
  • the detection reagent can be obtained, for example, by binding a labeling substance and a compound having a phosphocholine group represented by the formula (I). Further, for example, the detection reagent can also be obtained by binding the labeling substance and the compound having the phosphocholine group represented by the formula (I) to other carriers such as polymers and metal particles.
  • the present invention will be specifically described with reference to examples, but the present invention is not limited to these examples.
  • the phosphocholine group may be abbreviated as "PC”.
  • SH-PEG-NH 2 (molecular weight: 10 kDa) was dissolved in ethanol (20 mg/mL), and 2-methacryloyloxyethylphosphocholine (MPC, 10 equivalents) was added. After bubbling argon for 15 minutes, diisopropylamine (DIPA, 10 equivalents) was added, and the mixture was reacted at 30° C. for 48 hours. Ethanol was removed by vacuum drying, the polymer was dissolved in pure water, dialyzed against pure water (MWCO: 3,500), and then freeze-dried to obtain PC-PEG-NH 2 . From 1 H-NMR in deuterated chloroform, it was confirmed that the introduction rate of PC was 98%.
  • MPC 2-methacryloyloxyethylphosphocholine
  • DCM dichloromethane
  • DMF N,N-dimethylformamide
  • BLA-NCA
  • PC-PEG-PAsp was synthesized by deprotecting the benzyl ester of the side chain structure of the PBLA chain of PC-PEG-PBLA. Specifically, an aqueous sodium hydroxide solution (0.5 M, 380 equivalents) was added to PC-PEG-PBLA, and the mixture was reacted at room temperature for 1 hour. PC-PEG-PAsp was obtained by lyophilization after dialysis against pure water (MWCO: 6,000-8,000). From 1 H-NMR in heavy water, it was confirmed that the benzyl group was completely deprotected.
  • a control polymer (MeO-PEG-PAsp) having a methoxy group at the terminal and no PC was also synthesized in the same manner by the NCA polymerization method using MeO-PEG-NH 2 as an initiator and deprotection of the benzyl ester.
  • Homo-P (Asp-AP) was synthesized by aminolysis reaction of benzyl ester having a side chain structure of Homo-PBLA. Specifically, Homo-PBLA was dissolved in DCM (40 mg/mL), benzene (4 mg/mL) was added, and the mixture was freeze-dried. The polymer was dissolved in N-methyl-2-pyrrolidone (NMP), added to diaminopentane (DAP, 6,500 equivalents) in NMP, and reacted at 12 degrees for 1 hour. After neutralization with hydrochloric acid, dialysis against pure water (MWCO: 3,500) was performed, and freeze-drying gave Homo-P (Asp-AP).
  • NMP N-methyl-2-pyrrolidone
  • DAP diaminopentane
  • PC-PEG-PAsp and Homo-P (Asp-AP) were each dissolved in 10 mM phosphate buffer (pH 7.4), and the carboxyl group of PAsp chain PC primary PIC micelles were prepared by mixing so that the molar ratio of the primary amine of the P(Asp-AP) chain was 1. Further, non-PC-loaded PIC micelles were prepared in the same manner as above except that a control polymer (MeO-PEG-PAsp) was used instead of PC-PEG-PAsp as the control PIC micelle.
  • PIC polyion complex
  • PC-loaded PIC micelles were localized in mitochondria with a co-localization ratio several times higher than control non-PC-loaded PIC micelles.
  • PC-PEG-PAsp-Ac was dissolved in DMF (10 mg/mL) containing 10 mM LiCl, and EDC (345 equivalent), dimethylaminopyridine (DMAP, 345 equivalent) and simvastatin (345 equivalent) were added. did. After reacting at room temperature for 24 hours, it was added to an excess amount of diethyl ether and dried under reduced pressure to obtain PC-PEG-P(Asp-simvastatin)-Ac. The introduction rate of simvastatin calculated from 1 H-NMR in heavy DMF was 86%. The results are shown in Table 2.
  • a simvastatin-binding polymer without PC (MeO-PEG-P(Asp-simvastatin)-Ac) was obtained in the same manner as above except that MeO-PEG-PAsp was used instead of PC-PEG-PAsp. It was
  • a non-PC-loaded simvastatin-encapsulating micelle was prepared in the same manner as described above, except that MeO-PEG-P(Asp-simvastatin)-Ac was used instead of PC-PEG-P(Asp-simvastatin)-Ac. .. After purification with a filter, the size and PDI of micelles were measured by the DLS method, and the zeta potential of the micelles was measured by the ELS method. The results are shown in Table 2.
  • the PC-loaded simvastatin-encapsulated micelle solution was significantly lower than the simvastatin solution, and exhibited a slightly higher cytotoxicity than the non-PC-loaded simvastatin-encapsulated micelle solution. From this, it is understood that the cytotoxicity of simvastatin is remarkably suppressed by micellization, and that the cytotoxicity of simvastatin can be exerted even when micelle is formed by the increase of cell uptake due to the addition of PC.
  • PC-PEG-PGTrp The following PC-PEG-PGTrp was synthesized. The specific procedure is as follows. NH 2 -PEG-poly(Glycerol) (PEG molecular weight: 12 kDa, Glycerol polymerization degree: 80) was dissolved in pure water (30 mg/mL), and MPC (10 equivalents), EDC (10 equivalents), N-hydroxysuccinimide ( NHS-OH, 10 eq) was added. After 24 hours of reaction at room temperature, dialysis against pure water (MWCO: 6,000-8,000) was carried out, and freeze-dried to obtain PC-PEG-poly(Glycerol). The PC introduction rate was calculated from 1 H-NMR in heavy water to find that it was 73%.
  • PC-PEG-poly(Glycerol) was dissolved in DMF (10 mg/mL) and Fmoc-NH-tryptophan-OH (810 eq), EDC (810 eq) and DMAP (810 eq) were added. After the reaction at room temperature for 24 hours, it was added to an excess amount of diethyl ether and dried under reduced pressure to obtain PC-PEG-P (Glycidyl Tryptophan (Fmoc)). The introduction rate of Fmoc-NH-tryptophan-OH was calculated from 1 H-NMR in deuterated DMSO, and it was 88%.
  • PC-PEG-poly(Glycidyl Tryptophan (Fmoc)) was dissolved in DMF (10 mg/mL) containing 20% piperidine and reacted at room temperature for 24 hours. After the reaction, it was added to an excess amount of diethyl ether and dried under reduced pressure to obtain PC-PEG-PGTrp. Deprotection of the Fmoc group was confirmed by 1 H-NMR in heavy water. Further, a polymer without PC (MeO-PEG-PGTrp) was obtained in the same manner as above except that MeO-PEG-poly(Glycerol) was used instead of PC-PEG-poly(Glycerol).
  • PC-PEG-PGTrp and mRNA were dissolved in 10 mM Hepes buffer (pH 7.3), and primary amine (N) of PGTrp chain and mRNA were dissolved. The mixture was carried out so that the molar ratio (N/P) of the phosphate groups (P) in the mixture was 3 to prepare PC-loaded mRNA micelles. Further, non-PC-loaded mRNA micelles were prepared in the same manner as above except that MeO-PEG-PGTrp was used instead of PC-PEG-PGTrp. The size of mRNA micelles and PDI were measured by the DLS method. Further, the association number of mRNA molecules per one micelle was measured by the fluorescence correlation spectroscopy (FCS) method. The results are shown in Table 3.
  • PC-loaded mRNA micelles showed significantly higher gene expression efficiency than non-PC-loaded mRNA micelles. It is suggested that the gene expression efficiency was also increased by the increase in cell uptake due to the addition of PC.
  • the experimental group to which the albumin PC conjugate was added showed significantly higher fluorescence intensity than the experimental group to which albumin alone was added. This indicates that the cellular uptake of albumin PC conjugate was increased.
  • albumin PC conjugate was localized in mitochondria with a higher co-localization ratio than albumin alone. This shows that the drug can be efficiently delivered into mitochondria by binding PC to the drug.
  • BxPC3 cells human pancreatic adenocarcinoma cells
  • DLS dynamic light scattering method
  • the cells were trypsinized, collected by centrifugation, and prefixed and postfixed with a prefix solution (mixed solution of 4% paraformaldehyde, 0.1M PBS, 25% glutaraldehyde at 5:4:1). (1:1 mixed solution of 2% osmic acid and 0.1 PBS) was used for post-fixation. Then, ascending ethanol dehydration was performed, and after embedding with Epon resin, an ultrathin section was prepared by cutting with a diamond cutter to a thickness of 1 ⁇ m.
  • the obtained ultrathin section was stained with a uranium staining solution (uranium acetate, 50% alcohol solution), and then Reynolds lead staining solution (2.66 g of lead nitrate, 3.52 g of sodium citrate, 16 mL of 1M NaOH).
  • a uranium staining solution uranium acetate, 50% alcohol solution
  • Reynolds lead staining solution 2.66 g of lead nitrate, 3.52 g of sodium citrate, 16 mL of 1M NaOH.
  • FIG. 7A is a cross-sectional image of BxPC3 cells
  • FIG. 7B is an enlarged image of a portion surrounded by a square in FIG. 7A
  • mitochondria are imaged in the central portion. ..
  • FIG. 7( b ) a black spot based on the gold nanoparticles having PC groups bound thereto was observed inside the mitochondria, which indicates that the PC-loaded gold nanoparticles were taken up into the cells and then inside the mitochondria. It was confirmed that it was moved to.
  • the present invention can be preferably used in the DDS field, for example.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une technologie permettant d'administrer efficacement des médicaments à des cellules ou à des mitochondries. Ce conjugué de médicament comprend un médicament et un domaine de recherche de cible lié au médicament, le domaine de recherche de cible comprenant un groupe phosphocholine représenté par la formule (I).
PCT/JP2019/047917 2018-12-07 2019-12-06 Conjugué de médicament, conjugué de polymère et composition d'administration de médicament WO2020116640A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020560070A JPWO2020116640A1 (ja) 2018-12-07 2019-12-06 薬物複合体、ポリマー複合体及び薬物送達用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-229599 2018-12-07
JP2018229599 2018-12-07

Publications (1)

Publication Number Publication Date
WO2020116640A1 true WO2020116640A1 (fr) 2020-06-11

Family

ID=70974200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/047917 WO2020116640A1 (fr) 2018-12-07 2019-12-06 Conjugué de médicament, conjugué de polymère et composition d'administration de médicament

Country Status (2)

Country Link
JP (1) JPWO2020116640A1 (fr)
WO (1) WO2020116640A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554272B (zh) * 2022-09-28 2024-03-22 昆明理工大学 一种纳米颗粒的制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509976A (ja) * 1994-11-30 1998-09-29 アムール リサーチ コーポレーション ホスホコリン薬物誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509976A (ja) * 1994-11-30 1998-09-29 アムール リサーチ コーポレーション ホスホコリン薬物誘導体

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DING, K. ET AL.: "Folate Ligand Orientation Optimized during Cell Membrane Mimetic Micelle Formation for Enhanced Tumor Cell Targeting", LANGMUIR, vol. 35, no. 5, 24 June 2018 (2018-06-24), pages 1257 - 65, XP055722193, ISSN: 1520-5827 *
KHUNSUK, P.O. ET AL.: "Gold Nanorods Stabilized by Biocompatible and Multifunctional Zwitterionic Copolymer for Synergistic Cancer Therapy", MOL PHARM, vol. 15, no. 1, 2 January 2018 (2018-01-02), pages 164 - 74, XP055722195, ISSN: 1543-8384 *
LEWIS, A.L. ET AL.: "PC Technology as a platform for drug delivery: from combination to conjugation", EXPERT OPIN DRUG DELIV, vol. 3, no. 2, 28 February 2006 (2006-02-28), pages 289 - 98, XP055722192, ISSN: 1742-5247 *
LU , L. ET AL.: "Liposomes assembled from dimeric retinoic acid phospholipid with improved pharmacokinetic properties", EUR J PHARM SCI, vol. 112, 15 June 2018 (2018-06-15), pages 186 - 94, XP085319902, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2017.11.017 *
MINNELLI, C. ET AL.: "A Poloxamer-407 modified liposome encapsulating epigallocatechin-3-gallate in the presence of magnesium: Characterization and protective effect against oxidative damage", INT J PHARM, vol. 552, 1 December 2018 (2018-12-01), pages 225 - 34, XP085511848, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2018.10.004 *
OU, H. ET AL.: "Surface-adaptive zwitterionic nanoparticles for prolonged blood circulation time and enhanced cellular uptake in tumor cells", ACTA BIOMATER, vol. 65, 25 October 2017 (2017-10-25), pages 339 - 348, XP085289995, ISSN: 1742-7061, DOI: 10.1016/j.actbio.2017.10.034 *
WANG, W. ET AL.: "Tailor-Made a PH -Responsive Poly(choline phosphate) Prodrug as a Drug Delivery System for Rapid Cellular Internalization", BIOMACROMOLECULES, vol. 17, no. 6, 17 May 2016 (2016-05-17), pages 2223 - 2232, XP085289996, ISSN: 1525-7797 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554272B (zh) * 2022-09-28 2024-03-22 昆明理工大学 一种纳米颗粒的制备方法及其应用

Also Published As

Publication number Publication date
JPWO2020116640A1 (ja) 2021-10-21

Similar Documents

Publication Publication Date Title
Ofek et al. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers
Zhu et al. Dual-responsive polyplexes with enhanced disassembly and endosomal escape for efficient delivery of siRNA
Sun et al. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery
Wang et al. A pH-sensitive gene delivery system based on folic acid-PEG-chitosan–PAMAM-plasmid DNA complexes for cancer cell targeting
Kwon Diblock copolymer nanoparticles for drug delivery
Osada et al. Drug and gene delivery based on supramolecular assembly of PEG-polypeptide hybrid block copolymers
von Erlach et al. Formation and characterization of DNA-polymer-condensates based on poly (2-methyl-2-oxazoline) grafted poly (L-lysine) for non-viral delivery of therapeutic DNA
EP2087912B1 (fr) Support de parni utilisant une micelle polymérique à pont disulfure
Kano et al. Grafting of poly (ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA
JP4655298B1 (ja) 短鎖のカチオン性ポリアミノ酸およびその使用
Gheybi et al. Supramolecular anticancer drug delivery systems based on linear–dendritic copolymers
US8546487B2 (en) Cationic poly (amino acids) and uses thereof
US9114177B2 (en) Block copolymer having phenylboronic acid group introduced therein, and use thereof
JP5645186B2 (ja) 電荷変換型三元系ポリプレックス
Gao et al. Recent advances of dendrimers in delivery of genes and drugs
JP6797415B2 (ja) 薬剤送達用キャリア及びこれを含む組成物
Xu et al. Co-delivery of doxorubicin and P-glycoprotein siRNA by multifunctional triblock copolymers for enhanced anticancer efficacy in breast cancer cells
Luten et al. Degradable PEG-folate coated poly (DMAEA-co-BA) phosphazene-based polyplexes exhibit receptor-specific gene expression
Li et al. Reversibly cross-linked poly (ethylene glycol)–poly (amino acid) s copolymer micelles: a promising approach to overcome the extracellular stability versus intracellular drug release challenge
Salakhieva et al. Structure–biocompatibility and transfection activity relationships of cationic polyaspartamides with (dialkylamino) alkyl and alkyl or hydroxyalkyl side groups
Yang et al. Folate-modified poly (malic acid) graft polymeric nanoparticles for targeted delivery of doxorubicin: synthesis, characterization and folate receptor expressed cell specificity
Li et al. Self-assembled PEG-b-PDPA-b-PGEM copolymer nanoparticles as protein antigen delivery vehicles to dendritic cells: preparation, characterization and cellular uptake
WO2020116640A1 (fr) Conjugué de médicament, conjugué de polymère et composition d'administration de médicament
Martin et al. Cholesteryl to improve the cellular uptake of polymersomes within HeLa cells
Cao et al. Folic acid directly modified low molecular weight of polyethyleneimine for targeted pDNA delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19891842

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020560070

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19891842

Country of ref document: EP

Kind code of ref document: A1